타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor)) Daping Hospital and the Research I…·Colon Adenocarcinoma 1 trials | ||||
|---|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Praluent (alirocumab) | Leqvio (inclisiran) | Tolecizumab (PCSK9 Inhibitor) | PCSK9 inhibitor |
Overview Company | Amgen | Sanofi / Regeneron | Novartis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Yun Dai Chen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 | PCSK9 (siRNA) | Colon Adenocarcinoma | Acute Myocardial Infarction |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Colon Adenocarcinoma | Acute Myocardial Infarction |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PRECLINICAL |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Flexible q2w dosing; post-ACS outcomes label | Infrequent dosing (q6 months maintenance) | — | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | resistance to immune checkpoint blockade | Injection-site reactions; long-term siRNA durability generally maintained. | — | — |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | — | — |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, ApoB. | LDL-C, PCSK9 protein levels. | — | — |
Toxicology Species | Cynomolgus monkey, Hamster | Rat | Mouse, Rat | — | — |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | — | — |
Toxicology CRS | N/A | N/A | N/A | — | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PRECLINICAL |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor)) Daping Hospital and the Research I…·Colon Adenocarcinoma 1 trials | ||||
|---|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Praluent (alirocumab) | Leqvio (inclisiran) | Tolecizumab (PCSK9 Inhibitor) | PCSK9 inhibitor |
Overview Company | Amgen | Sanofi / Regeneron | Novartis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Yun Dai Chen |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 | PCSK9 (siRNA) | Colon Adenocarcinoma | Acute Myocardial Infarction |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Colon Adenocarcinoma | Acute Myocardial Infarction |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PRECLINICAL |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Flexible q2w dosing; post-ACS outcomes label | Infrequent dosing (q6 months maintenance) | — | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | resistance to immune checkpoint blockade | Injection-site reactions; long-term siRNA durability generally maintained. | — | — |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | — | — |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, ApoB. | LDL-C, PCSK9 protein levels. | — | — |
Toxicology Species | Cynomolgus monkey, Hamster | Rat | Mouse, Rat | — | — |
Toxicology Animal (cat.) | NHP | — | — | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | — | — |
Toxicology CRS | N/A | N/A | N/A | — | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, flu-like symptoms. | Injection-site reactions, arthralgia, urinary tract infection. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_2 | PRECLINICAL |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — | — | — |
추천 비교
추천 비교